[144] Datadog, Inc. SEC Filing

Rhea-AI Filing Summary

Datadog, Inc. filed a Form 144 notifying a proposed sale of 63,939 Class A common shares to be effected through Morgan Stanley Smith Barney LLC on 10/09/2025. The filing lists an aggregate market value of $10,493,668.68 for the shares and reports total shares outstanding of 323,270,704. The shares were originally acquired as founders' shares on 07/08/2010. The notice also documents multiple prior sales under a Rule 10b5-1 plan and an individual sale by Olivier Pomel between 07/28/2025 and 10/08/2025, with several trades in August, September and October 2025. The filer certifies they are not aware of undisclosed material adverse information.

Positive

• Long-term ownership: Shares were acquired as founders' shares on 07/08/2010
• Rule-based selling: Multiple recent trades executed under a 10b5-1 plan, indicating pre-arranged dispositions

Negative

• Planned sale size: 63,939 Class A shares proposed for sale on 10/09/2025
• Ongoing insider sales: Numerous 10b5-1 trades and an individual sale by Olivier Pomel during Jul–Oct 2025 increase insider share supply

Insights

Insider Transactions Analyst

Insider plans show orderly, pre-arranged sales rather than one-time liquidity event.

The filing reports a scheduled sale of 63,939 Class A shares on 10/09/2025

Most recent activity is executed under a 10b5-1 plan across July–October 2025, which typically indicates pre-set, rule-compliant dispositions rather than opportunistic insider trades. Key dependencies include adherence to the plan trading schedule and market execution by the listed broker. Monitor the 10/09/2025 settlement and any additional filings that update volumes or cancel the notice within days of that date.

Corporate Governance Specialist

Founders' long-term holding history reduces immediate governance concern but sales are material to insider liquidity.

The securities were acquired as founders' shares on 07/08/2010, showing a long holding period which can be seen as alignment with shareholders. However, ongoing programmatic sales by a named executive and planned disposition of 63,939 shares create continuing insider supply.

Watch for disclosures tied to insider liquidity or any statements altering trading plans; any change in the trading cadence or additional large notices within the next weeks would be relevant to governance and insider-sentiment assessment.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	63939	10493668.68	323270704	10/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/08/2010	Founders Shares	Issuer			63939	07/08/2010	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales Plan for OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	10/08/2025	25620	4227449.10
10b5-1 Sales Plan for OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	10/07/2025	21728	3355359.44
10b5-1 Sales Plan for OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	10/07/2025	11195	1728794.59
10b5-1 Sales Plan for OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	09/23/2025	11195	1544269.65
10b5-1 Sales Plan for OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	09/08/2025	21728	2950308.23
10b5-1 Sales Plan for OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	09/08/2025	11195	1518540.18
OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	09/02/2025	15357	2055491.45
10b5-1 Sales Plan for OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	08/27/2025	11195	1455350.00
10b5-1 Sales Plan for OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	08/11/2025	21728	2827234.32
10b5-1 Sales Plan for OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	08/11/2025	11195	1465101.96
10b5-1 Sales Plan for OLIVIER POMEL 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	07/28/2025	11195	1688462.37

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is the proposed sale reported in the Datadog (DDOG) Form 144?

The notice reports a proposed sale of 63,939 Class A common shares with an aggregate market value of $10,493,668.68, planned for 10/09/2025 through Morgan Stanley Smith Barney LLC.

Who originally acquired the shares being sold in the DDOG Form 144?

The shares were acquired as founders' shares on 07/08/2010 from the issuer; the filing lists the acquisition date as 07/08/2010.

Have there been recent insider sales for Datadog disclosed in the filing?

Yes; the filing lists multiple sales executed under a 10b5-1 plan and one direct sale by Olivier Pomel between 07/28/2025 and 10/08/2025.

How many Datadog shares are outstanding per the Form 144?

The document reports 323,270,704 shares outstanding.

Does the filer state there is undisclosed material information?

By signing the notice, the filer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.